Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56<sup>bright</sup>CD16<sup>−</sup> subsetIrene Veneziani, Enrico Maggi|Journal for ImmunoTherapy of Cancer|2022Cited by 43